메뉴 건너뛰기




Volumn 22, Issue 5, 2005, Pages 405-417

Pharmacological management of severe postmenopausal osteoporosis

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; STRONTIUM RANELATE; TAMOXIFEN; ZOLEDRONIC ACID;

EID: 22344456666     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200522050-00005     Document Type: Review
Times cited : (9)

References (68)
  • 1
    • 0033802496 scopus 로고    scopus 로고
    • Risk of mortality following clinical fractures
    • Cauley JA. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556-61
    • (2000) Osteoporos Int , vol.11 , pp. 556-561
    • Cauley, J.A.1
  • 3
    • 0035406305 scopus 로고    scopus 로고
    • 2001 Medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis
    • American Association of Clinical Endocrinologists
    • Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists. 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract. 2001; 7 (4): 293-312
    • (2001) Endocr Pract. , vol.7 , Issue.4 , pp. 293-312
    • Hodgson, S.F.1    Watts, N.B.2    Bilezikian, J.P.3
  • 5
    • 0034719619 scopus 로고    scopus 로고
    • Osteoporosis prevention, diagnosis and therapy
    • National Institutes of Health (USA). Osteoporosis prevention, diagnosis and therapy. NIH Consensus Statements 2000; 17 (1): 1-45
    • (2000) NIH Consensus Statements , vol.17 , Issue.1 , pp. 1-45
  • 7
    • 0029890161 scopus 로고    scopus 로고
    • Hip fracture
    • Zuckerman JD. Hip fracture. N Engl J Med 1996; 334: 1519-25
    • (1996) N Engl J Med , vol.334 , pp. 1519-1525
    • Zuckerman, J.D.1
  • 8
    • 0033550968 scopus 로고    scopus 로고
    • Mortality after all major types of osteoporotic fracture in men and women: An observational study
    • Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-82
    • (1999) Lancet , vol.353 , pp. 878-882
    • Center, J.R.1    Nguyen, T.V.2    Schneider, D.3
  • 9
    • 0033553866 scopus 로고    scopus 로고
    • Vertebral fractures and mortality in older women
    • Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women. Arch Intern Med 1999; 159: 1215-20
    • (1999) Arch Intern Med , vol.159 , pp. 1215-1220
    • Kado, D.M.1    Browner, W.S.2    Palermo, L.3
  • 10
    • 0026515737 scopus 로고
    • Incidence of clinically diagnosed vertebral fractures: A population based study in Rochester, Minnesota, 1985-1989
    • Cooper C, Atkinson EJ, O'Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992; 7: 221-7
    • (1992) J Bone Miner Res , vol.7 , pp. 221-227
    • Cooper, C.1    Atkinson, E.J.2    O'Fallon, W.M.3
  • 11
    • 0035900949 scopus 로고    scopus 로고
    • Risk of new vertebral fracture in the year following a fracture
    • Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-3
    • (2001) JAMA , vol.285 , pp. 320-323
    • Lindsay, R.1    Silverman, S.L.2    Cooper, C.3
  • 12
    • 0034022318 scopus 로고    scopus 로고
    • Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
    • Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 4: 721-39
    • (2000) J Bone Miner Res , vol.4 , pp. 721-739
    • Klotzbuecher, C.M.1    Ross, P.D.2    Landsman, P.B.3
  • 13
    • 0032951747 scopus 로고    scopus 로고
    • Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures
    • Black DM, Arden NK, Palmero L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 1999; 14: 821-8
    • (1999) J Bone Miner Res , vol.14 , pp. 821-828
    • Black, D.M.1    Arden, N.K.2    Palmero, L.3
  • 14
    • 1642443292 scopus 로고    scopus 로고
    • Confronting osteoporosis: What we know, where we're headed
    • Davidson M, DeSimone ME. Confronting osteoporosis: what we know, where we're headed. Clin Rev 2002; 12: 76-82
    • (2002) Clin Rev , vol.12 , pp. 76-82
    • Davidson, M.1    DeSimone, M.E.2
  • 15
    • 0034707104 scopus 로고    scopus 로고
    • Prevention of hip fracture in elderly people with use of a hip protector
    • Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000; 343: 1506-13
    • (2000) N Engl J Med , vol.343 , pp. 1506-1513
    • Kannus, P.1    Parkkari, J.2    Niemi, S.3
  • 16
    • 0028949069 scopus 로고
    • Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
    • Reid IR, Ames RW, Evans MC, et al. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995; 98: 331-5
    • (1995) Am J Med , vol.98 , pp. 331-335
    • Reid, I.R.1    Ames, R.W.2    Evans, M.C.3
  • 17
    • 0030826193 scopus 로고    scopus 로고
    • Calcium for prevention of osteoporotic fractures in postmenopausal women
    • Cumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res 1997; 12: 1321-9
    • (1997) J Bone Miner Res , vol.12 , pp. 1321-1329
    • Cumming, R.G.1    Nevitt, M.C.2
  • 18
    • 0030763532 scopus 로고    scopus 로고
    • Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
    • Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6
    • (1997) N Engl J Med , vol.337 , pp. 670-676
    • Dawson-Hughes, B.1    Harris, S.S.2    Krall, E.A.3
  • 19
    • 0031803314 scopus 로고    scopus 로고
    • The role of calcium and vitamin D in the prevention of osteoporosis
    • Reid IR. The role of calcium and vitamin D in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998; 27: 389-98
    • (1998) Endocrinol Metab Clin North Am , vol.27 , pp. 389-398
    • Reid, I.R.1
  • 20
    • 0030038417 scopus 로고    scopus 로고
    • Vitamin D supplementation and fracture incidence in elderly persons
    • Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med 1996; 124: 400-6
    • (1996) Ann Intern Med , vol.124 , pp. 400-406
    • Lips, P.1    Graafmans, W.C.2    Ooms, M.E.3
  • 21
    • 0031036965 scopus 로고    scopus 로고
    • Bisphosphonates: Preclinical aspects and use in osteoporosis
    • Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 1997; 29: 55-62
    • (1997) Ann Med , vol.29 , pp. 55-62
    • Fleisch, H.A.1
  • 22
    • 0033065233 scopus 로고    scopus 로고
    • Bisphosphonates: From the laboratory to the clinic and back again
    • Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106
    • (1999) Bone , vol.25 , pp. 97-106
    • Russell, R.G.1    Rogers, M.J.2
  • 23
    • 0032583492 scopus 로고    scopus 로고
    • Effect of alendronate on risk of fracture in women with low bone Associadensity but without vertebral fractures: Results from the Fracture Intervention Trial
    • Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone Associadensity but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82
    • (1998) JAMA , vol.280 , pp. 2077-2082
    • Cummings, S.R.1    Black, D.M.2    Thompson, D.E.3
  • 24
    • 0032896590 scopus 로고    scopus 로고
    • Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
    • Fosamax International Trial Study Group
    • Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9: 461-8
    • (1999) Osteoporos Int , vol.9 , pp. 461-468
    • Pols, H.A.1    Felsenberg, D.2    Hanley, D.A.3
  • 25
    • 0033552255 scopus 로고    scopus 로고
    • Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
    • Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
    • Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52
    • (1999) JAMA , vol.282 , pp. 1344-1352
    • Harris, S.T.1    Watts, N.B.2    Genant, H.K.3
  • 26
    • 0029116697 scopus 로고
    • Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
    • Chesnut III CH, McClung M, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99: 144-52
    • (1995) Am J Med , vol.99 , pp. 144-152
    • Chesnut III, C.H.1    McClung, M.2    Ensrud, K.E.3
  • 27
    • 0028851590 scopus 로고
    • Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
    • Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43
    • (1995) N Engl J Med , vol.333 , pp. 1437-1443
    • Liberman, U.A.1    Weiss, S.R.2    Broll, J.3
  • 28
    • 0032767389 scopus 로고    scopus 로고
    • Alendronate increases bone density and bone strength at the distal radius in postmenopausal women
    • Schneider PF, Fischer M, Allolio B, et al. Alendronate increases bone density and bone strength at the distal radius in postmenopausal women. J Bone Miner Res 1999; 14: 1387-93
    • (1999) J Bone Miner Res , vol.14 , pp. 1387-1393
    • Schneider, P.F.1    Fischer, M.2    Allolio, B.3
  • 29
    • 0004851872 scopus 로고    scopus 로고
    • Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group
    • Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41
    • (1996) Lancet , vol.348 , pp. 1535-1541
    • Black, D.M.1    Cummings, S.R.2    Karpf, D.B.3
  • 30
    • 0034097152 scopus 로고    scopus 로고
    • Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis
    • Milano
    • Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging (Milano) 2000; 12: 1-12
    • (2000) Aging , vol.12 , pp. 1-12
    • Schnitzer, T.1    Bone, H.G.2    Crepaldi, G.3
  • 31
    • 0036828449 scopus 로고    scopus 로고
    • Alendronate Once-Weekly Study Group: Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis
    • Rizzoli R, Greenspan SL, Bone III G, et al. Alendronate Once-Weekly Study Group: two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17 (11): 1988-96
    • (2002) J Bone Miner Res , vol.17 , Issue.11 , pp. 1988-1996
    • Rizzoli, R.1    Greenspan, S.L.2    Bone III, G.3
  • 32
    • 12144289279 scopus 로고    scopus 로고
    • Alendronate Phase III Osteoporosis Treatment Study Group: Ten years' experience with alendronate for osteoporosis in postmenopausal women
    • Bone HG, Hosking D, Devogelaer JP, et al. Alendronate Phase III Osteoporosis Treatment Study Group: ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350 (12): 1189-99
    • (2004) N Engl J Med , vol.350 , Issue.12 , pp. 1189-1199
    • Bone, H.G.1    Hosking, D.2    Devogelaer, J.P.3
  • 33
    • 0030868816 scopus 로고    scopus 로고
    • Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
    • Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475-80
    • (1997) J Clin Invest , vol.100 , pp. 1475-1480
    • Chavassieux, P.M.1    Arlot, M.E.2    Reda, C.3
  • 34
    • 0033755981 scopus 로고    scopus 로고
    • Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women
    • Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000; 27: 687-94
    • (2000) Bone , vol.27 , pp. 687-694
    • Boivin, G.Y.1    Chavassieux, P.M.2    Santora, A.C.3
  • 35
    • 0035996567 scopus 로고    scopus 로고
    • Changes in bone remodeling rate influence the degree of mineralization of bone
    • Boivin G, Meunier PJ. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 2002; 43: 535-7
    • (2002) Connect Tissue Res , vol.43 , pp. 535-537
    • Boivin, G.1    Meunier, P.J.2
  • 36
    • 14644399915 scopus 로고    scopus 로고
    • Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension
    • Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004; 19: 1259-69
    • (2004) J Bone Miner Res , vol.19 , pp. 1259-1269
    • Ensrud, K.E.1    Barrett-Connor, E.L.2    Schwartz, A.3
  • 37
    • 0037156445 scopus 로고    scopus 로고
    • Gastric and duodenal safety of daily alendronate
    • Apr 22
    • Donahue JG, Chan KA, Andrade SE, et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002 Apr 22; 162 (8): 936-42
    • (2002) Arch Intern Med , vol.162 , Issue.8 , pp. 936-942
    • Donahue, J.G.1    Chan, K.A.2    Andrade, S.E.3
  • 39
    • 0035253489 scopus 로고    scopus 로고
    • Effects of risedronate on the risk of hip fracture in elderly women
    • McClung MR, Geusens P, Miller PD, et al. Effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40
    • (2001) N Engl J Med , vol.344 , pp. 333-340
    • McClung, M.R.1    Geusens, P.2    Miller, P.D.3
  • 40
    • 0031057249 scopus 로고    scopus 로고
    • Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study
    • Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15: 955-62
    • (1997) J Clin Oncol , vol.15 , pp. 955-962
    • Delmas, P.D.1    Balena, R.2    Confravreux, E.3
  • 41
    • 12944291524 scopus 로고    scopus 로고
    • Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
    • Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91
    • (2000) Osteoporos Int , vol.11 , pp. 83-91
    • Reginster, J.Y.1    Minne, H.W.2    Sorensen, O.H.3
  • 42
    • 0037326110 scopus 로고    scopus 로고
    • Risedronate prevents new vertebral fractures in postmenopausal women at high risk
    • Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. JCEM 2003; 88: 542-9
    • (2003) JCEM , vol.88 , pp. 542-549
    • Watts, N.B.1    Josse, R.G.2    Hamdy, R.C.3
  • 43
    • 11144354206 scopus 로고    scopus 로고
    • Efficacy of risedronate on clinical vertebral fractures within six months
    • Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004; 20 (4): 433-9
    • (2004) Curr Med Res Opin , vol.20 , Issue.4 , pp. 433-439
    • Roux, C.1    Seeman, E.2    Eastell, R.3
  • 44
    • 1342281219 scopus 로고    scopus 로고
    • Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis
    • Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 74 (2): 129-35
    • (2004) Calcif Tissue Int , vol.74 , Issue.2 , pp. 129-135
    • Harrington, J.T.1    Ste-Marie, L.G.2    Brandi, M.L.3
  • 45
    • 0036690206 scopus 로고    scopus 로고
    • The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis
    • Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-11
    • (2002) Calcif Tissue Int , vol.71 , pp. 103-111
    • Brown, J.P.1    Kendler, D.L.2    McClung, M.R.3
  • 46
    • 0037291756 scopus 로고    scopus 로고
    • Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience
    • Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003; 32 (2): 120-6
    • (2003) Bone , vol.32 , Issue.2 , pp. 120-126
    • Sorensen, O.H.1    Crawford, G.M.2    Mulder, H.3
  • 47
    • 12944323192 scopus 로고    scopus 로고
    • Seven years of treatment with risedronate in women with postmenopausal osteoporosis
    • Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75 (6): 462-8
    • (2004) Calcif Tissue Int , vol.75 , Issue.6 , pp. 462-468
    • Mellstrom, D.D.1    Sorensen, O.H.2    Goemaere, S.3
  • 49
    • 0033016224 scopus 로고    scopus 로고
    • Effect of calcitonin on vertebral and other fractures
    • Kanis JA, McCloskey EV. Effect of calcitonin on vertebral and other fractures. QJM 1999; 92: 143-9
    • (1999) QJM , vol.92 , pp. 143-149
    • Kanis, J.A.1    McCloskey, E.V.2
  • 50
    • 0033829969 scopus 로고    scopus 로고
    • A randomized trial of nasal spray salmon calcitonin in postmenopausal wo-men with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study
    • Chesnut III CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal wo-men with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000; 109: 267-76
    • (2000) Am J Med , vol.109 , pp. 267-276
    • Chesnut III, C.H.1    Silverman, S.2    Andriano, K.3
  • 51
    • 0036852676 scopus 로고    scopus 로고
    • The analgesic role of calcitonin follow-ing osteoporotic fracture
    • Silverman SL, Azria M. The analgesic role of calcitonin follow-ing osteoporotic fracture. Osteoporos Int 2002; 13: 858-67
    • (2002) Osteoporos Int , vol.13 , pp. 858-867
    • Silverman, S.L.1    Azria, M.2
  • 52
    • 0033431687 scopus 로고    scopus 로고
    • Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: A prospective double-blind, randomized, placebo-controlled clinical study
    • Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999; 15: 284-9
    • (1999) Clin J Pain , vol.15 , pp. 284-289
    • Lyritis, G.P.1    Ioannidis, G.V.2    Karachalios, T.3
  • 54
    • 0032416079 scopus 로고    scopus 로고
    • Selective estrogen receptors modulators: A new category of therapeutic agents for extending the health of postmenopausal women
    • Goldstein SR. Selective estrogen receptors modulators: a new category of therapeutic agents for extending the health of postmenopausal women. Am J Obstet Gynecol 1998; 179: 1479-8
    • (1998) Am J Obstet Gynecol , vol.179 , pp. 1479-1488
    • Goldstein, S.R.1
  • 55
    • 0033515045 scopus 로고    scopus 로고
    • Clinical effects of raloxifene hydrochloride in women
    • Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999; 130: 431-9
    • (1999) Ann Intern Med , vol.130 , pp. 431-439
    • Khovidhunkit, W.1    Shoback, D.M.2
  • 56
    • 2642712522 scopus 로고    scopus 로고
    • Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
    • Walsh BW, Kuller LH, Wild R, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51
    • (1998) JAMA , vol.279 , pp. 1445-1451
    • Walsh, B.W.1    Kuller, L.H.2    Wild, R.3
  • 57
    • 0033581212 scopus 로고    scopus 로고
    • Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
    • Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282: 637-45
    • (1999) JAMA , vol.282 , pp. 637-645
    • Ettinger, B.1    Black, D.M.2    Mitlak, B.H.3
  • 58
    • 0033575083 scopus 로고    scopus 로고
    • The effect of raloxifene on risk of breast cancer in postmenopausal women
    • Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189-97
    • (1999) JAMA , vol.281 , pp. 2189-2197
    • Cummings, S.R.1    Eckert, S.2    Krueger, K.A.3
  • 59
    • 2642712522 scopus 로고    scopus 로고
    • Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
    • Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51
    • (1998) JAMA , vol.279 , pp. 1445-1451
    • Walsh, B.W.1    Kuller, L.H.2    Wild, R.A.3
  • 60
    • 0030015080 scopus 로고    scopus 로고
    • A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
    • Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835-42
    • (1996) J Bone Miner Res , vol.11 , pp. 835-842
    • Draper, M.W.1    Flowers, D.E.2    Huster, W.J.3
  • 61
    • 0030664688 scopus 로고    scopus 로고
    • Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
    • Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7
    • (1997) N Engl J Med , vol.337 , pp. 1641-1647
    • Delmas, P.D.1    Bjarnason, N.H.2    Mitlak, B.H.3
  • 62
    • 32744462785 scopus 로고    scopus 로고
    • Osteoporosis indication approval recommended with restrictions: FDA Endocrinological and Metabolic Drugs Advisory Committee
    • Jul 30
    • Lilly Forteo. Osteoporosis indication approval recommended with restrictions: FDA Endocrinological and Metabolic Drugs Advisory Committee. Pink Sheet 2001 Jul 30; 63 (31): 3
    • (2001) Pink Sheet , vol.63 , Issue.31 , pp. 3
    • Forteo, L.1
  • 63
    • 0032746174 scopus 로고    scopus 로고
    • Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone
    • Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-46
    • (1999) J Clin Invest , vol.104 , pp. 439-446
    • Jilka, R.L.1    Weinstein, R.S.2    Bellido, T.3
  • 64
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women with osteoporosis
    • Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fracture and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41
    • (2001) N Engl J Med , vol.344 , pp. 1434-1441
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3
  • 65
    • 3242762388 scopus 로고    scopus 로고
    • Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
    • Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19 (5): 745-51
    • (2004) J Bone Miner Res , vol.19 , Issue.5 , pp. 745-751
    • Ettinger, B.1    San Martin, J.2    Crans, G.3
  • 66
    • 0037186926 scopus 로고    scopus 로고
    • Intravenous zoledronic acid in postmenopausal women with low bone mineral density
    • Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61
    • (2002) N Engl J Med , vol.346 , pp. 653-661
    • Reid, I.R.1    Brown, J.P.2    Burckhardt, P.3
  • 67
    • 4544262219 scopus 로고    scopus 로고
    • Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
    • Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9
    • (2004) J Bone Miner Res , vol.19 , pp. 1241-1249
    • Chesnut III, C.H.1    Skag, A.2    Christiansen, C.3
  • 68
    • 9144233479 scopus 로고    scopus 로고
    • The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
    • Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350 (5): 459-68
    • (2004) N Engl J Med , vol.350 , Issue.5 , pp. 459-468
    • Meunier, P.J.1    Roux, C.2    Seeman, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.